Welcome to our dedicated page for 10X Genomics news (Ticker: TXG), a resource for investors and traders seeking the latest updates and insights on 10X Genomics stock.
10X Genomics, Inc. (TXG) drives innovation in life sciences through advanced single cell and spatial biology solutions. This news hub provides investors and researchers with essential updates about technological advancements, strategic partnerships, and financial developments shaping the future of biological research.
Access authoritative information on product launches, peer-reviewed study validations, and regulatory milestones. Our curated collection includes earnings reports, executive commentary, and analyses of how TXG's platforms enable breakthroughs in oncology, immunology, and neuroscience research.
Key updates cover instrument innovations, software enhancements, and collaborations with leading research organizations. Monitor progress in making high-resolution cellular analysis more accessible to academic institutions and biopharmaceutical developers worldwide.
Bookmark this page for streamlined access to verified TXG developments. Check regularly for insights into how the company continues redefining biological discovery through integrated hardware, consumables, and data analysis solutions.
10x Genomics (Nasdaq: TXG) announced its participation in the 41st Annual Cowen Health Care Conference on March 3 at 2 p.m. Eastern Time. The presentation will be accessible via a live and archived webcast on the company's website. 10x Genomics is focused on advanced life science technologies, with products adopted by top research institutions and pharmaceutical companies globally. The company boasts a robust patent portfolio with over 1,000 patents and has been cited in over 2,200 research papers in various fields.
10x Genomics (Nasdaq: TXG) has announced the acquisition of Tetramer Shop and unveiled new products at its Xperience 2021 event. This marks the fifth acquisition for the firm, aimed at bolstering its immunology efforts. The newly introduced products focus on single-cell analysis, with significant capabilities like the Low Throughput Single Cell Gene Expression solution, expected to lower startup costs by up to 60%. Other upcoming innovations include Chromium X, Visium advancements, and a new cloud platform for data analysis, enhancing accessibility for researchers.
10x Genomics reported Q4 2020 revenue of $112.2 million, a 49% increase from the previous year, and a full-year revenue of $298.8 million, up 22% year-over-year. The company had a gross margin of 83% in Q4, up from 78% in Q4 2019, driven by a shift in product sales. However, operating expenses surged to $502.9 million, resulting in an operating loss of $409.6 million. For 2021, 10x Genomics projects revenue between $480 million and $500 million, reflecting a growth outlook of 61% to 67%.
10x Genomics (TXG) has announced that it will release its financial results for Q4 and full year ended December 31, 2020, after the market close on February 17, 2021. A conference call to discuss the results and company outlook will begin at 1:30 PM PT. The event will be accessible via webcast on the company's website and archived for replay for 45 days. 10x Genomics focuses on life science technology, providing solutions that enhance biological understanding, serving major global research institutions and pharmaceutical companies.
10x Genomics (Nasdaq: TXG) will participate in the 39th Annual J.P. Morgan Virtual Healthcare Conference, scheduled for January 11, 2021, at 7:00 a.m. PT / 10:00 a.m. ET. The company's management will present key information, and interested parties can access a live and archived webcast on their Investors page.
10x Genomics develops integrated solutions for biological research, with products widely adopted by leading research institutions and pharmaceutical companies.
10x Genomics, Inc. (TXG) reported Q3 2020 revenue of $71.8 million, a 17% increase year-over-year and a 67% increase from Q2 2020. The company made significant acquisitions of ReadCoor and CartaNA, enhancing its capabilities in In Situ analysis. Despite revenue growth, operating expenses surged 124% to $122.7 million, leading to an operating loss of $65.3 million and a net loss of $65.8 million. The company has withdrawn its full-year revenue guidance due to ongoing COVID-19 uncertainties.
10x Genomics (Nasdaq: TXG) will participate in the Stifel Virtual Healthcare Conference on November 16 at 11:40 a.m. PT. The presentation will be accessible via a live and archived webcast on the company’s investors page.
10x Genomics offers advanced products for biological analysis, utilized by 97 of the top 100 research institutions and 19 of the top 20 pharmaceutical companies. With over 1,750 citations in research, the company holds a patent portfolio of more than 825 patents and applications.
10x Genomics (TXG) will report its third-quarter financial results on November 10, 2020, post-market. A conference call will follow at 2:00 PM PT to discuss outcomes, business developments, and future outlook.
The event will be available for live audio streaming on the company’s website, with a recording accessible for 45 days thereafter. 10x Genomics specializes in life science technologies, offering comprehensive solutions for biological analysis, widely adopted by leading research institutions and pharmaceutical companies.
10x Genomics (Nasdaq: TXG) announced a definitive agreement to acquire ReadCoor, a developer of In Situ technologies, for $350 million in cash and stock. This follows the acquisition of CartaNA AB, enhancing 10x's capabilities in In Situ RNA analysis. Together, these acquisitions are expected to develop comprehensive intellectual property and technology in the emerging In Situ field, potentially establishing a new technology platform and broadening customer applications. The ReadCoor acquisition is anticipated to complete later this month, subject to shareholder approval.
10x Genomics, Inc. (NASDAQ: TXG) announced the successful closing of a public offering for 4,600,000 shares of its Class A common stock, including the full exercise of an underwriters’ option for an additional 600,000 shares. Priced at $110.00 per share, the total gross proceeds amounted to $506 million prior to underwriting discounts and expenses. J.P. Morgan Securities LLC, BofA Securities, and Cowen and Company acted as lead managers. Registration statements for this offering were effective as of September 10, 2020.
